The short version of Reverse-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Neurotransmitter receptors and receptor ionophores. Nicotinic, imidazoline I1 and I2, α2-adrenergic, glutamate NMDAr, and serotonin 5-HT2A and 5HT-3 receptors. Ion channels. Including: ATP-sensitive K+ channels, voltage-gated Ca2+ channels, and acid-sensing ion channels (ASICs). Membrane transporters. Agmatine specific-selective uptake sites, organic cation transporters (mostly OCT2 subtype), extraneuronal monoamine transporters (ENT), polyamine transporters, and mitochondrial agmatine specific-selective transport system. Nitric oxide (NO) synthesis modulation. Both differential inhibition and activation of NO synthase (NOS) isoforms is reported. Polyamine metabolism. Agmatine is a precursor for polyamine synthesis, competitive inhibitor of polyamine transport, inducer of spermidine/spermine acetyltransferase (SSAT), and inducer of antizyme. Protein ADP-ribosylation. Inhibition of protein arginine ADP-ribosylation. Matrix metalloproteases (MMPs). Indirect down-regulation of the enzymes MMP 2 and 9. Advanced glycation end product (AGE) formation. Direct blockade of AGEs formation. NADPH oxidase. Activation of the enzyme leading to H2O2 production.
== Current Scenario of bsAb drugs == Several bsAb drugs have been approved by the US FDA / EMA and over 180 are currently in clinical trials. The first bispecific antibody to gain regulatory approval, blinatumomab, targets CD19 on B cells and CD3 on T cells, leading to the activation of T cells and the destruction of B cells. Additional bispecific antibody drugs have since been approved by the US FDA: emicizumab, amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab, epcoritamab, glofitamab. Among the bsAb programs currently under development, the combination of CD3 and tumor surface targets are the most popular targets pairs. Other popular targets are HER2, PD-1, PD-L1, EGFR, CTLA-4, etc., which as well as immune targets of PD-1, PD-L1, BCMA, CD47, CTLA-4, LAG-3, 4 -1BB. Additionally, with the approval of the several new bsAb since 2022, and new mechanisms for improving efficacy like development of hetero-dimer bispecific molecules, several additional possibilities of target pairs have emerged.
=== Fragment-based === The most common of these uses a group contribution method and is termed cLogP. It has been shown that the log P of a compound can be determined by the sum of its non-overlapping molecular fragments (defined as one or more atoms covalently bound to each other within the molecule). Fragmentary log P values have been determined in a statistical method analogous to the atomic methods (least-squares fitting to a training set). In addition, Hammett-type corrections are included to account of electronic and steric effects. This method in general gives better results than atomic-based methods, but cannot be used to predict partition coefficients for molecules containing unusual functional groups for which the method has not yet been parameterized (most likely because of the lack of experimental data for molecules containing such functional groups).
Aromatic L-amino acid decarboxylase deficiency, also known as AADC deficiency, is a rare genetic disorder caused by mutations in the DDC gene, which encodes an enzyme called aromatic L-amino acid decarboxylase.
Sources: en.wikipedia.org
Copper-free click chemistry is being explored for use in synthesizing PET imaging agents which must be made quickly with high purity and yield in order to minimize isotopic decay before the compounds can be administered. Both the high rate constants and the bioorthogonality of SPAAC are amenable to PET chemistry.
=== EC 1.14.13 With NADH or NADPH as one donor, and incorporation of one atom of oxygen into the other donor === EC 1.14.13.1: salicylate 1-monooxygenase EC 1.14.13.2: 4-hydroxybenzoate 3-monooxygenase EC 1.14.13.3: Now EC 1.14.14.9, 4-hydroxyphenylacetate 3-monooxygenase EC 1.14.13.4: melilotate 3-monooxygenase EC 1.14.13.5: imidazoleacetate 4-monooxygenase EC 1.14.13.6: orcinol 2-monooxygenase EC 1.14.13.7: phenol 2-monooxygenase EC 1.14.13.8: flavin-containing monooxygenase EC 1.14.13.9: kynurenine 3-monooxygenase EC 1.14.13.10: 2,6-dihydroxypyridine 3-monooxygenase EC 1.14.13.11: Now EC 1.14.14.91, trans-cinnamate 4-monooxygenase EC 1.14.13.12: Now EC 1.14.14.92, benzoate 4-monooxygenase EC 1.14.13.13: Now classified as EC 1.14.15.18, calcidiol 1-monooxygenase EC 1.14.13.14: trans-cinnamate 2-monooxygenase EC 1.14.13.15: Now EC 1.14.15.15, cholestanetriol 26-monooxygenase EC 1.14.13.16: cyclopentanone monooxygenase EC 1.14.13.17: Now EC 1.14.14.23, cholesterol 7α-monooxygenase EC 1.14.13.18: 4-hydroxyphenylacetate 1-monooxygenase EC 1.14.13.19: taxifolin 8-monooxygenase EC 1.14.13.20: 2,4-dichlorophenol 6-monooxygenase EC 1.14.13.21: Now EC 1.14.14.82, flavonoid 3′-monooxygenase EC 1.14.13.22: cyclohexanone monooxygenase EC 1.14.13.23: 3-hydroxybenzoate 4-monooxygenase EC 1.14.13.24: 3-hydroxybenzoate 6-monooxygenase EC 1.14.13.25: methane monooxygenase (soluble) EC 1.14.13.26: Now classified as EC 1.14.18.4, phosphatidylcholine 12-monooxygenase EC 1.14.13.27: 4-aminobenzoate 1-monooxygenase EC 1.14.13.28: Now EC 1.14.14.93, 3,9-dihydroxypterocarpan 6a-monooxygenase EC 1.14.13.29: 4-nitrophenol 2-monooxygenase EC 1.14.13.30: Now EC 1.14.14.94, leukotriene-B4 20-monooxygenase EC 1.14.13.31: 2-nitrophenol 2-monooxygenase EC 1.14.13.32: albendazole monooxygenase EC 1.14.13.33: 4-hydroxybenzoate 3-monooxygenase (NAD(P)H) EC 1.14.13.34: leukotriene-E4 20-monooxygenase EC 1.14.13.35: anthranilate 3-monooxygenase (deaminating) EC 1.14.13.36: Now EC 1.14.14.96, 5-O-(4-coumaroyl)-D-quinate 3′-monooxygenase EC 1.14.13.37: Now EC 1.14.14.97, methyltetrahydroprotoberberine 14-monooxygenase EC 1.14.13.38: anhydrotetracycline monooxygenase EC 1.14.13.39: nitric-oxide synthase EC 1.14.13.40: anthraniloyl-CoA monooxygenase EC 1.14.13.41: Now EC 1.14.14.36, tyrosine N-monooxygenase EC 1.14.13.42: The activity is covered by EC 1.14.13.68, 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.13.43: questin monooxygenase EC 1.14.13.44: 2-hydroxybiphenyl 3-monooxygenase EC 1.14.13.45: Now EC 1.14.18.2, CMP-N-acetylneuraminate monooxygenase EC 1.14.13.46: (-)-menthol monooxygenase EC 1.14.13.47: Now EC 1.14.14.99, (S)-limonene 3-monooxygenase EC 1.14.13.48: Now classified as EC 1.14.14.51, (S)-limonene 6-monooxygenase EC 1.14.13.49: Now classified as EC 1.14.14.52, (S)-limonene 7-monooxygenase EC 1.14.13.50: pentachlorophenol monooxygenase EC 1.14.13.51: 6-oxocineole dehydrogenase EC 1.14.13.52: Now EC 1.14.14.88, isoflavone 3′-hydroxylase EC 1.14.13.53: Now EC 1.14.14.89, 4′-methoxyisoflavone 2′-hydroxylase EC 1.14.13.54: ketosteroid monooxygenase EC 1.14.13.55: Now EC 1.14.14.98, protopine 6-monooxygenase EC 1.14.13.56: Now EC 1.14.14.100, dihydrosanguinarine 10-monooxygenase EC 1.14.13.57: Now EC 1.14.14.101, dihydrochelirubine 12-monooxygenase EC 1.14.13.58: benzoyl-CoA 3-monooxygenase EC 1.14.13.59: L-lysine N6-monooxygenase (NADPH) EC 1.14.13.60: Now included with EC 1.14.13.100, 25-hydroxycholesterol 7α-hydroxylase EC 1.14.13.61: 2-hydroxyquinoline 8-monooxygenase EC 1.14.13.62: 4-hydroxyquinoline 3-monooxygenase EC 1.14.13.63: 3-hydroxyphenylacetate 6-hydroxylase EC 1.14.13.64: 4-hydroxybenzoate 1-hydroxylase EC 1.14.13.65: deleted EC 1.14.13.66: 2-hydroxycyclohexanone 2-monooxygenase EC 1.14.13.67: Now EC 1.14.14.55, quinine 3-monooxygenase EC 1.14.13.68: Now EC 1.14.14.37, 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.13.69: alkene monooxygenase EC 1.14.13.70: Now EC 1.14.14.154, sterol 14α-demethylase EC 1.14.13.71: Now EC 1.14.14.102, N-methylcoclaurine 3′-monooxygenase EC 1.14.13.72: Now classified as EC 1.14.18.9, methylsterol monooxygenase EC 1.14.13.73: Now EC 1.14.14.103, tabersonine 16-hydroxylase EC 1.14.13.74: Now EC 1.14.14.85, 7-deoxyloganin 7-hydroxylase EC 1.14.13.75: Now EC 1.14.14.104, vinorine hydroxylase EC 1.14.13.76: Now EC 1.14.14.105, taxane 10β-hydroxylase EC 1.14.13.77: Now EC 1.14.14.106, taxane 13α-hydroxylase EC 1.14.13.78: Now EC 1.14.14.86, ent-kaurene monooxygenase EC 1.14.13.79: Now EC 1.14.14.107, ent-kaurenoic acid oxidase EC 1.14.13.80: Now classified as EC 1.14.14.53, (R)-limonene 6-monooxygenase EC 1.14.13.81: magnesium-protoporphyrin IX monomethyl ester (oxidative) cyclase EC 1.14.13.82: vanillate monooxygenase EC 1.14.13.83: precorrin-3B synthase EC 1.14.13.84: 4-hydroxyacetophenone monooxygenase EC 1.14.13.85: Now EC 1.14.14.135, glyceollin synthase EC 1.14.13.86: The activity is covered by EC 1.14.14.87, 2-hydroxyisoflavanone synthase EC 1.14.13.87: Now EC 1.14.14.140, licodione synthase] EC 1.14.13.88: Now EC 1.14.14.81, flavanoid 3,5-hydroxylase EC 1.14.13.89: Now EC 1.14.14.90, isoflavone 2-hydroxylase EC 1.14.13.90: Now EC 1.14.15.21, zeaxanthin epoxidase EC 1.14.13.91: Now EC 1.14.14.136, deoxysarpagine hydroxylase EC 1.14.13.92: phenylacetone monooxygenase EC 1.14.13.93: Now EC 1.14.14.137, (+)-abscisic acid 8-hydroxylase EC 1.14.13.94: Now EC 1.14.14.138, lithocholate 6β-hydroxylase EC 1.14.13.95: Now included with EC 1.14.14.139, 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.13.96: Now EC 1.14.14.139, 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.13.97: Now EC 1.14.14.57, taurochenodeoxycholate 6α-hydroxylase EC 1.14.13.98: Now EC 1.14.14.25, cholesterol 24-hydroxylase EC 1.14.13.99: Now EC 1.14.14.26, 24-hydroxycholesterol 7α-hydroxylase EC 1.14.13.100: Now classified as EC 1.14.14.29, 25/26-hydroxycholesterol 7α-hydroxylase EC 1.14.13.101: senecionine N-oxygenase EC 1.14.13.102: Now EC 1.14.14.141, psoralen synthase EC 1.14.13.103: Now EC 1.14.14.142, 8-dimethylallylnaringenin 2-hydroxylase EC 1.14.13.104: Now EC 1.14.14.143, (+)-menthofuran synthase EC 1.14.13.105: monocyclic monoterpene ketone monooxygenase EC 1.14.13.106: now classified as EC 1.14.15.39, epi-isozizaene 5-monooxygenase. EC 1.14.13.107: limonene 1,2-monooxygenase EC 1.14.13.108: Now EC 1.14.14.144, abieta-7,13-diene hydroxylase EC 1.14.13.109: Now EC 1.14.14.145, abieta-7,13-dien-18-ol hydroxylase EC 1.14.13.110: Now EC 1.14.14.146, geranylgeraniol 18-hydroxylase EC 1.14.13.111: methanesulfonate monooxygenase EC 1.14.13.112: Now EC 1.14.14.147, 3-epi-6-deoxocathasterone 23-monooxygenase EC 1.14.13.113: FAD-dependent urate hydroxylase EC 1.14.13.114: 6-hydroxynicotinate 3-monooxygenase EC 1.14.13.115: Now EC 1.14.14.148, angelicin synthase EC 1.14.13.116: Now EC 1.14.14.174, geranylhydroquinone 3-hydroxylase EC 1.14.13.117: Now EC 1.14.14.39, isoleucine N-monooxygenase EC 1.14.13.118: Now EC 1.14.14.38, valine N-monooxygenase EC 1.14.13.119: Now EC 1.14.14.149, 5-epiaristolochene 1,3-dihydroxylase EC 1.14.13.120: Now EC 1.14.14.150, costunolide synthase EC 1.14.13.121: Now EC 1.14.14.151, premnaspirodiene oxygenase EC 1.14.13.122: chlorophyllide-a oxygenase EC 1.14.13.123: Now EC 1.14.14.95, germacrene A hydroxylase EC 1.14.13.124: now classified as EC 1.14.14.40, phenylalanine N-monooxygenase EC 1.14.13.125: Now EC 1.14.14.156, tryptophan N-monooxygenase EC 1.14.13.126: Now EC 1.14.15.16, vitamin D3 24-hydroxylase EC 1.14.13.127: 3-(3-hydroxyphenyl)propanoate hydroxylase EC 1.14.13.128: 7-methylxanthine demethylase EC 1.14.13.129: Now EC 1.14.15.24, β-carotene 3-hydroxylase EC 1.14.13.130: pyrrole-2-carboxylate monooxygenase EC 1.14.13.131: dimethyl-sulfide monooxygenase EC 1.14.13.132: Now EC 1.14.14.17, squalene monooxygenase EC 1.14.13.133: Now EC 1.14.15.32, pentalenene oxygenase EC 1.14.13.134: Now EC 1.14.14.152, β-amyrin 11-oxidase EC 1.14.13.135: 1-hydroxy-2-naphthoate hydroxylase EC 1.14.13.136: Now EC 1.14.14.87, 2-hydroxyisoflavanone synthase EC 1.14.13.137: Now EC 1.14.14.153, indole-2-monooxygenase EC 1.14.13.138: Now EC 1.14.14.157, indolin-2-one monooxygenase EC 1.14.13.139: Now EC 1.14.14.109, 3-hydroxyindolin-2-one monooxygenase EC 1.14.13.140: Now EC 1.14.14.110, 2-hydroxy-1,4-benzoxazin-3-one monooxygenase. EC 1.14.13.141: Now EC 1.14.15.29, cholest-4-en-3-one 26-monooxygenase [(25S)-3-oxocholest-4-en-26-oate forming] EC 1.14.13.142: Now EC 1.14.15.30, 3-ketosteroid 9α-monooxygenase EC 1.14.13.143: Now EC 1.14.14.76 ent-isokaurene C2/C3-hydroxylase EC 1.14.13.144: Now EC 1.14.14.111, 9β-pimara-7,15-diene oxidase EC 1.14.13.145: Now EC 1.14.14.112, ent-cassa-12,15-diene 11-hydroxylase EC 1.14.13.146: taxoid 14β-hydroxylase EC 1.14.13.147: Now EC 1.14.14.182, taxoid 7β-hydroxylase EC 1.14.13.148: trimethylamine monooxygenase EC 1.14.13.149: phenylacetyl-CoA 1,2-epoxidase EC 1.14.13.150: Now EC 1.14.14.113, α-humulene 10-hydroxylase EC 1.14.13.151: Now EC 1.14.14.84, linalool 8-monooxygenase EC 1.14.13.152: Now EC 1.14.14.83, geraniol 8-hydroxylase EC 1.14.13.153: (+)-sabinene 3-hydroxylase EC 1.14.13.154: erythromycin 12-hydroxylase EC 1.14.13.155: α-pinene monooxygenase EC 1.14.13.156: Now EC 1.14.14.133, 1,8-cineole 2-endo-monooxygenase EC 1.14.13.157: Now EC 1.14.14.56, 1,8-cineole 2-exo-monooxygenase EC 1.14.13.158: Now EC 1.14.14.114, amorpha-4,11-diene 12-monooxygenase EC 1.14.13.159: Now EC 1.14.14.24, vitamin D 25-hydroxylase EC 1.14.13.160: (2,2,3-trimethyl-5-oxocyclopent-3-enyl)acetyl-CoA 1,5-monooxygenase EC 1.14.13.161: (+)-camphor 6-exo-hydroxylase EC 1.14.13.162: Now EC 1.14.14.108, 2,5-diketocamphane 1,2-monooxygenase EC 1.14.13.163: 6-hydroxy-3-succinoylpyridine 3-monooxygenase EC 1.14.13.164: withdrawn: see EC 1.13.11.65, carotenoid isomerooxygenase EC 1.14.13.165: Now classified as EC 1.14.14.47, nitric-oxide synthase (flavodoxin) EC 1.14.13.166: 4-nitrocatechol 4-monooxygenase EC 1.14.13.167: 4-nitrophenol 4-monooxygenase EC 1.14.13.168: indole-3-pyruvate monooxygenase EC 1.14.13.169: Now EC 1.14.18.5, sphingolipid C4-monooxygenase EC 1.14.13.170: pentalenolactone D synthase EC 1.14.13.171: neopentalenolactone D synthase EC 1.14.13.172: salicylate 5-hydroxylase EC 1.14.13.173: Now EC 1.14.14.115, 11-oxo-β-amyrin 30-oxidase EC 1.14.13.174: Now EC 1.14.14.116, averantin hydroxylase EC 1.14.13.175: Now EC 1.14.14.117, aflatoxin B synthase EC 1.14.13.176: Now EC 1.14.14.118, tryprostatin B 6-hydroxylase EC 1.14.13.177: Now EC 1.14.14.119, fumitremorgin C monooxygenase EC 1.14.13.178: methylxanthine N1-demethylase EC 1.14.13.179: methylxanthine N3-demethylase EC 1.14.13.180: aklavinone 12-hydroxylase EC 1.14.13.181: 13-deoxydaunorubicin hydroxylase EC 1.14.13.182: 2-heptyl-3-hydroxy-4(1H)-quinolone synthase EC 1.14.13.183: Now EC 1.14.14.120, dammarenediol 12-hydroxylase EC 1.14.13.184: Now EC 1.14.14.121, protopanaxadiol 6-hydroxylase EC 1.14.13.185: Now EC 1.14.15.33, pikromycin synthase EC 1.14.13.186: Now EC 1.14.15.34, 20-oxo-5-O-mycaminosyltylactone 23-monooxygenase EC 1.14.13.187: L-evernosamine nitrososynthase EC 1.14.13.188: Now EC 1.14.15.35, 6-deoxyerythronolide B hydroxylase EC 1.14.13.189: 5-methyl-1-naphthoate 3-hydroxylase EC 1.14.13.190: Now EC 1.14.14.175, ferruginol synthase EC 1.14.13.191: Now EC 1.14.14.70, ent-sandaracopimaradiene 3-hydroxylase EC 1.14.13.192: Now EC 1.14.14.122, oryzalexin E synthase EC 1.14.13.193: Now EC 1.14.14.123, oryzalexin D synthase EC 1.14.13.194: Now EC 1.14.14.78, phylloquinone ω-hydroxylase EC 1.14.13.195: L-ornithine N5-monooxygenase (NADPH) EC 1.14.13.196: L-ornithine N5-monooxygenase [NAD(P)H] EC 1.14.13.197: Now EC 1.14.14.124, dihydromonacolin L hydroxylase EC 1.14.13.198: Now EC 1.14.14.125, monacolin L hydroxylase EC 1.14.13.199: Now EC 1.14.14.79, docosahexaenoic acid ω-hydroxylase EC 1.14.13.200: tetracenomycin A2 monooxygenase-dioxygenase EC 1.14.13.201: Now EC 1.14.14.126, β-amyrin 28-monooxygenase EC 1.14.13.202: Now EC 1.14.14.127, methyl farnesoate epoxidase EC 1.14.13.203: Now EC 1.14.14.128, farnesoate epoxidase EC 1.14.13.204: Now EC 1.14.14.129, long-chain acyl-CoA ω-monooxygenase EC 1.14.13.205: Now EC 1.14.14.80, long-chain fatty acid ω-monooxygenase EC 1.14.13.206: Now EC 1.14.14.130, laurate 7-monooxygenase EC 1.14.13.207: Now EC 1.14.14.31, ipsdienol synthase EC 1.14.13.208: benzoyl-CoA 2,3-epoxidase EC 1.14.13.209: salicyloyl-CoA 5-hydroxylase EC 1.14.13.210: 4-methyl-5-nitrocatechol 5-monooxygenase EC 1.14.13.211: rifampicin monooxygenase EC 1.14.13.212: 1,3,7-trimethyluric acid 5-monooxygenase EC 1.14.13.213: Now EC 1.14.14.131, bursehernin 5-monooxygenase EC 1.14.13.214: Now EC 1.14.14.132, (–)-4′-demethyl-deoxypodophyllotoxin 4-hydroxylase EC 1.14.13.215: protoasukamycin 4-monooxygenase EC 1.14.13.216: asperlicin C monooxygenase EC 1.14.13.217: protodeoxyviolaceinate monooxygenase EC 1.14.13.218: 5-methylphenazine-1-carboxylate 1-monooxygenase EC 1.14.13.219: resorcinol 4-hydroxylase (NADPH) EC 1.14.13.220: resorcinol 4-hydroxylase (NADH) EC 1.14.13.221: Now EC 1.14.15.28, cholest-4-en-3-one 26-monooxygenase [(25R)-3-oxocholest-4-en-26-oate forming] EC 1.14.13.222: aurachin C monooxygenase/isomerase EC 1.14.13.223: 3-hydroxy-4-methylanthranilyl-[aryl-carrier protein] 5-monooxygenase EC 1.14.13.224: violacein synthase EC 1.14.13.225: F-actin monooxygenase EC 1.14.13.226: acetone monooxygenase (methyl acetate-forming) EC 1.14.13.227: propane 2-monooxygenase EC 1.14.13.228: jasmonic acid 12-hydroxylase EC 1.14.13.229: tert-butyl alcohol monooxygenase EC 1.14.13.230: butane monooxygenase (soluble) EC 1.14.13.231: tetracycline 11a-monooxygenase EC 1.14.13.232: 6-methylpretetramide 4-monooxygenase EC 1.14.13.233: 4-hydroxy-6-methylpretetramide 12a-monooxygenase EC 1.14.13.234: 5a,11a-dehydrotetracycline 5-monooxygenase EC 1.14.13.235: indole-3-acetate monooxygenase EC 1.14.13.236: toluene 4-monooxygenase EC 1.14.13.237: aliphatic glucosinolate S-oxygenase EC 1.14.13.238: dimethylamine monooxygenase EC 1.14.13.239: carnitine monooxygenase EC 1.14.13.240: 2-polyprenylphenol 6-hydroxylase EC 1.14.13.241: 5-pyridoxate monooxygenase EC 1.14.13.242: 3-hydroxy-2-methylpyridine-5-carboxylate monooxygenase EC 1.14.13.243: toluene 2-monooxygenase EC 1.14.13.244: phenol 2-monooxygenase (NADH) EC 1.14.13.245: assimilatory dimethylsulfide S-monooxygenase EC 1.14.13.246: 4β-methylsterol monooxygenase EC 1.14.13.247: stachydrine N-demethylase
The serous membrane (or serosa) is a smooth epithelial membrane of mesothelium lining the contents and inner walls of body cavities, which secrete serous fluid to allow lubricated sliding movements between opposing surfaces. The serous membrane that covers internal organs (viscera) is called visceral, while the one that covers the cavity wall is called parietal. For instance the parietal peritoneum is attached to the abdominal wall and the pelvic walls. The visceral peritoneum is wrapped around the visceral organs. For the heart, the layers of the serous membrane are called parietal and visceral pericardium. For the lungs they are called parietal and visceral pleura. The visceral serosa of the uterus is called the perimetrium. The potential space between two opposing serosal surfaces is mostly empty except for the small amount of serous fluid. The Latin anatomical name is tunica serosa. Serous membranes line and enclose several body cavities, also known as serous cavities, where they secrete a lubricating fluid which reduces friction from movements. Serosa is entirely different from the adventitia, a connective tissue layer which binds together structures rather than reducing friction between them. The serous membrane covering the heart and lining the mediastinum is referred to as the pericardium, the serous membrane lining the thoracic cavity and surrounding the lungs is referred to as the pleura, and that lining the abdominopelvic cavity and the viscera is referred to as the peritoneum.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.